Survival of patients with bronchogenic carcinoma modified by BCG immunotherapy.
Fifty-five patients with stage II and III bronchogenic carcinoma were randomized into one group of 21 treated conventionally, and another group of 34 additionally vaccinated with BCG. Vaccinated patients survived, on average, 11 weeks longer than controls. A lag of about six months existed before consistent differences became apparent.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000276:immunology; D002277:Carcinoma / Q000276:immunology / Q000628:therapy; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D001500:BCG Vaccine